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Background: In a previous report, a clinical ST131 Escherichia coli isolate (Ec-1),
producing a plasmid-encoded AmpC β-lactamase CMY-2, evolved in vivo under
cefepime (FEP) treatment to the FEP-resistant Ec-2 strain expressing an extended-
spectrum β-lactamase CMY-33. To compare factors responsible for in vitro and in vivo
FEP resistance, we reproduced in vitro FEP resistance evolution in Ec-1.
Methods: FEP-resistant mutants were generated by subjecting Ec-1 (FEP
MIC = 0.125 mg/L) to sub-inhibitory concentrations of FEP. MICs were obtained by
broth microdilution or Etest. Strains were sequenced on an Illumina HiSeq platform.
Transcriptional levels and plasmid copy numbers were determined by real-time PCR.
Outer membrane proteins (OMPs) were extracted and separated by SDS-PAGE. Growth
kinetics was evaluated by measuring OD450.
Results: The CMY-2 expressed by Ec-1 evolved to a CMY-69 (strain EC-4) by an
Ala294Pro substitution after 24 passages. After 30 passages, the FEP MIC increased
to 256 mg/L (strain EC-32). SDS PAGE did not reveal any lack of OMPs in the mutant
strains. However, blaCMY transcription levels were up to 14-times higher than in Ec-1,
which was partially explained by mutations in the upstream region of repA resulting in a
higher copy number of the blaCMY-harboring IncI1 plasmid. All mutants showed a slight
growth defect but no significant difference in relative growth rates compared to Ec-1.
Conclusion: In vitro sub-inhibitory concentrations of FEP resulted in the selection of
resistance mutations altering the H-10 helix of the CMY-2 and increasing the plasmid
copy number. Appropriate dosing strategies may help preventing resistance evolution
during treatments.
Keywords: CMY-2, CMY-69, WGS, resistance evolution, ST131, cefepime
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INTRODUCTION
Cefepime (FEP) consumption in Swiss hospitals is among
the highest in Europe (Pluss-Suard et al., 2012). This 4th
generation cephalosporin is relatively stable to hydrolysis
through chromosomally encoded AmpC β-lactamases, and
therefore represents the treatment of choice in AmpC producers
that do not harbor extended-spectrum beta-lactamase enzymes
(ESBLs) (Harris and Ferguson, 2012; Hilty et al., 2013) or class
A or B carbapenemases, which are able to hydrolyze the drug
(Endimiani et al., 2008).
CMY-2 is a plasmid-encoded AmpC (pAmpC)
β-lactamase deriving from the chromosomally encoded
AmpC of Citrobacter freundii (Bauernfeind et al., 1996).
The blaCMY−2 gene is often located on large plasmids
of the IncI and IncA/C incompatibility groups, which
have been identified in Escherichia coli and other
Enterobacteriaceae worldwide (Philippon et al., 2002;
Baudry et al., 2009).
Escherichia coli expressing plasmid-mediated CMY-2 are
usually still susceptible to FEP. However, in the past, resistance
to FEP has sporadically been reported in E. coli with de-
repressed AmpCs and in strains with compounding porin
deficiencies (Mammeri et al., 2007, 2010; Haenni et al., 2014).
More recently, FEP-resistant E. coli isolates producing extended-
spectrum AmpCs (pESACs) have been described, which arose
through two to four amino acid deletions in the H-10 helix of
the CMY-2 (Doi et al., 2009). Notably, the in vivo development of
FEP-resistance under FEP treatment through the evolution of a
pAmpC CMY-2 to a pESAC CMY-33 has been recently reported
in a hyperepidemic sequence type (ST) 131 E. coli clone (Pires
et al., 2015). In this report, the FEP-susceptible E. coli isolate Ec-1
evolved to the FEP-resistant Ec-2 isolate as a consequence of a 6-
bp deletion in the blaCMY−2 gene harbored on an IncI1 plasmid,
which resulted in a Leu293-Ala294 deletion in the H-10 helix that
expanded the substrate spectrum of the enzyme. The authors also
confirm the absence of any ESBL genes by CT-103 Checkpoint
Microarray, which was important to rule out any potential
contribution of such β-lactamases to the observed phenotype.
In fact, differentiation of strains expressing AmpCs and ESBLs
based on their 3rd and 4th generation cephalosporin-resistance
can be challenging due to overlaps in the resistance phenotype
(Jacoby, 2009). For instance, the presence of ESBLs can be masked
by high-level AmpC production (EUCAST, version 6.0, 2016).
On the other hand, AmpC-producers typically test positive for
the ESBL screening test, but negative in the confirmatory test.
However, this phenotype may also be observed in peculiar TEM
mutants, strains harboring OXA-type ESBLs or carbapenemases
or expressing high levels of blaTEM−1. This scenario is further
complicated by the emergence of strains co-harboring pAmpC
and ESBL-genes (Ghosh and Mukherjee, 2016).
In this study, we reproduced in vitro the FEP-resistance
evolution in the original FEP-susceptible E. coli isolate Ec-1
by gradually subjecting the strain to increasing sublethal drug
concentrations. The objective was to determine the role of the
blaCMY in the resistance evolution and to identify hotspots
for mutations responsible for FEP resistance. We also aimed
to compare mechanisms evolved in vitro with those observed
in vivo, and assess the in vitro fitness of the resistant mutants.
MATERIALS AND METHODS
Bacterial Strains
The E. coli clinical isolates Ec-1 expressing blaCMY−2 and Ec-2
expressing blaCMY−33 used in this work were isolated as part of a
previous study (Pires et al., 2015). The porin-deficient mutants
E. coli MH513 MC4100 araD+ 8(ompF::lacZ) and MH225
MC4100 malQ7 8(ompC::lacZ) were described in a previous
study (Liu and Ferenci, 1998).
Antimicrobial Susceptibility Testing
The MICs for several antibiotics were determined by broth
microdilution in Mueller–Hinton broth (BBL, Becton
Dickinson) using the Sensititre GNX2F and ESB1F plates
(Trek Diagnostic Systems). MIC values were interpreted
in accordance with the 2016 European Committee on
Antimicrobial Susceptibility Testing (EUCAST) criteria
(version 6.0, 2016), besides for cephalothin, cefoxitin and
polymyxin B, for which clinical and laboratory standards
institute (CLSI) criteria (M100-S26, 2016) were applied. MICs
were also determined in the presence of the eﬄux pump
inhibitor phenyl-arginine-β-naphthylamide (PaβN) (Sigma-
Aldrich) at a final concentration of 25 mg/L and 10.4 mg/L
(Saw et al., 2016). MICs for FEP were additionally determined by
Etest (BioMérieux).
Serial Passages
Strain Ec-1 and its derivatives were passaged in the presence of
sub-inhibitory concentrations ( 14 of the respective MIC) of FEP.
Briefly, one single colony of Ec-1 grown ON at 37◦C on a cation-
adjusted Mueller-Hinton agar plate was picked and grown in
10 ml of cation-adjusted Mueller-Hinton broth at 37◦C for 24 h.
Then, 50 µl were inoculated into 10 ml cation-adjusted Mueller-
Hinton broth containing a FEP concentration at 14 of the initial
MIC of the strain and incubated at 37◦C for 24 h with shaking
at 120 rpm (first passage). Subsequently, 50 ul of the resulting
culture were diluted in 10 ml cation-adjusted Mueller-Hinton
broth with the same FEP concentration and incubated at 37◦C
for 24 h for two additional times (second and third passage).
After these three successive passages in the subinhibitory broth,
50 ul of the broth were diluted and streaked onto a cation-
adjusted Mueller-Hinton agar plate which was incubated ON
at 37◦C. Three representative colonies were randomly selected
from the plate and frozen at −80◦C for further analysis. The
three selected clones were subjected to MALDI-TOF analysis
to exclude contaminations and the FEP MIC (MICFEP) and the
blaCMY gene type were determined by Etest and PCR/Sanger
sequencing, respectively. One clone was then randomly chosen
to repeat the passages in subinhibitory broth as described above,
with the FEP concentrations for the subsequent three passages
increased according to the MIC results, i.e., 14 of the MIC.
The same procedure was also performed in parallel without
antibiotic pressure (negative controls). Aliquots of the bacterial
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cultures were regularly sampled and kept at −80◦C for further
molecular investigations.
Detection of Sequence Alterations in
blaCMY and Whole Genome Sequencing
The strains were subjected to Sanger sequencing of the
blaCMY-coding region amplified using the primers listed in
Supplementary Table S1. Total DNA was extracted from the
strains with the QiaAMP Mini Kit (Qiagen) and used to
construct libraries with the Nextera DNA Library Prep Kit
(Illumina) following manufacturer’s instructions. The libraries
were sequenced on an Illumina HiSeq platform (Illumina)
using the 2 × 150 bp paired-end sequencing protocol. Reads
were trimmed with Trimmomatic v.0.33 (Bolger et al., 2014)
and de novo assemblies were subsequently performed with
SPAdes v.3.9.0 (Bankevich et al., 2012). STs based on multi-
locus sequence typing (MLST), plasmid replicon types and the
presence of resistance genes were determined in silico on an
online platform (Center for Genomic Epidemiology1) using
MLST 1.8, PlasmidFinder 1.3, and ResFinder 2.1, respectively.
For single nucleotide polymorphism (SNP) and indel analysis,
read-mappings of the Illumina reads to the assembled reference
sequences were performed with BWA-MEM v0.7.13 (Zhu et al.,
2013) with default settings and subsequently analyzed with
the Geneious software v.10.2.32 (Kearse et al., 2012). Filtering
parameters for variant calling were a minimum variant frequency
of 0.8 and a maximum variant P-value of 10−6. The read-
mappings were also used to confirm that the mutant strains were
deriving from the parental strain.
Evaluation of Transcription Levels and
Plasmid Copy Number
Real-time PCR was used to measure mRNA expression levels
of blaCMY, ompF, ompC and the relative copy number of IncI1
replicon region with primers listed in Supplementary Table S1.
For the determination of changes in mRNA expression levels
between the parental and derivative strains of blaCMY, ompF
and ompC, mid-logarithmic growth cultures (0.5 ml) were
taken and treated with RNAprotect reagent (Qiagen). RNA
was extracted with RNeasy Mini Kit (Qiagen) and the
eluate was treated with DNase I (Qiagen) according to the
manufacturer’s instruction. The reverse transcription (RT)-PCR
was subsequently performed using the Power SYBR R©Green RNA-
to-CT 1-Step Kit (Thermo Fisher Scientific) and a QuantStudio
7 Flex Real-Time PCR System (Thermo Fisher Scientific) using
an annealing temperature of 60◦C. Transcript measurements
were carried out in triplicate and relative quantification of target
genes was calculated with the 2−11CT method using rpoD as a
reference (Sauer et al., 2004; Marcoleta et al., 2016), as described
previously (Livak and Schmittgen, 2001), with the original
susceptible strain Ec-1 used as the calibrator (Supplementary
Table S1). To assess a correlation between changes in blaCMY
transcription and plasmid copy numbers, total DNA from mid-
logarithmic growth cultures was extracted using the Qiagen
1https://cge.cbs.dtu.dk/services/
2http://www.geneious.com
DNeasy Mini Kit (Qiagen) and treated with RNase according to
the manufacturer’s instructions. Real-time PCR was performed
as described above, using the extracted DNA as template. Data
analysis was performed as described above, using the single-copy
chromosomal gene ampD for normalization.
Examination of Porin Expression
Outer membrane proteins (OMPs) were extracted according to
the rapid procedure of Carlone et al. (1986). Briefly, cells were
disrupted with FastPrep homogeniser (MP Biosciences) using
glass beads (Sigma-Aldrich) for four cycles of 50 s at 4 m/s.
After washing steps with 10 mM HEPES, the membrane pellets
were suspended in 50 µl of 10 mM HEPES and stored at
−80◦C. This procedure routinely yields preparations containing
approximately 2 mg of protein per ml. E. coli.MH513 and MH225
were used as reference strains for OmpC and OmpF expression,
respectively. Protein amounts were measured using Nanodrop
(Thermo Fischer Scientific). The proteins were precipitated with
acetone and resuspended in 20 µl of solubilization buffer. Fifteen
microliter of protein-buffer solution were separated on a 10%
Laemmli SDS-PAGE gel (Laemmli, 1970).
Bacterial Growth Curves
Cultures were grown overnight at 37◦C in cation-adjusted
Mueller-Hinton broth. Cells were then diluted 1:1000 in fresh
cation-adjusted Mueller-Hinton broth before inoculation in
quadruplicate on a 96 well plate. The plate was placed inside a
tunable microplate reader (Versamax, Molecular Devices), which
was programmed with the Softmax Pro software (Molecular
Devices) to incubate the plate at 37◦C and measure the optical
density at 450 nm (OD450) every 30 min for 22 h. Three biological
replicates were performed for each strain.
To estimate generation times, the exponential phase for each
strain was first estimated and confirmed by linear regression
of the lnOD450 values. Two time points within the exponential
phase (ODf and ODi) were then chosen to calculate the
generation time, as done previously Lange et al. (2018). Relative
growth rates were calculated by dividing the generation time of
the mutant strain with that of the parental strain. The obtained
relative growth rates were subsequently subjected to a two-tailed
t-test, in order to identify statistically significant differences in the
relative growth rate of the mutant strains and the parental strain
Ec-1, for which the relative growth rate was set to 1.
Nucleotide Accession Numbers
The whole-genome shotgun sequences of Ec-1 and its derivative
resistant strains are deposited in DDBJ/ENA/GenBank under
the following accession numbers: Ec-1, QEVU00000000;
EC-4, QDKR00000000; EC-16, QDKS00000000; EC-32,
QDKT00000000; and Ec-2, QDKU00000000.
RESULTS
In vitro FEP Resistance Evolution
Ec-1 with an initial MICFEP of 0.125 mg/L evolved to EC-4
with an intermediate resistance to FEP (MICFEP = 4 mg/L)
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after 24 passages in broth containing sub-inhibitory
concentrations of FEP. After 27 passages, EC-16, resistant
to FEP (MICFEP = 32 mg/L), and after 30 passages EC-32,
highly resistant to FEP (MICFEP = 256 mg/L), were obtained.
The MICFEP of the in vivo evolved mutant strain Ec-2 was
48 mg/L. The addition of the eﬄux pump inhibitor PaβN at
concentrations of 10.4 and 25 mg/L did not change the MICFEP
in any of the strains.
The MICs for different antibiotics for Ec-1 and the in vitro
(EC-4, EC-16, and EC-32) and in vivo (Ec-2) derivative resistant
strains are listed in Table 1. Of note, Ec-1, Ec-2, and EC-4 were
susceptible to piperacillin-tazobactam, whereas EC-16 and EC-32
were resistant (MIC> 64 mg/L).
Molecular Characterization of the
Resistant Mutants
PCR amplification and Sanger sequencing of the blaCMY-coding
region indicated that in EC-4, EC16 and EC-32, the CMY-2 had
evolved to a CMY-69 due to the SNP G940C resulting in an
Ala294Pro substitution [based on the amino acid numbering
scheme of Enterobacter cloacae P99 (Galleni et al., 1988)] in the
H-10 helix (Supplementary Figure S1). These mutations were
subsequently confirmed by whole-genome sequencing (WGS),
while no mutations in the promoter region of blaCMY were found
in any of the resistant strains compared to Ec-1. No transposition
or duplication of the gene was detected in the assemblies and the
absence of any ESBL genes was confirmed by in silico analysis in
the parental strain and its derivatives.
SNPs were found within the hairpin loop region of the inc
gene located on the IncI1 plasmid, consisting of a G24T mutation
in the in vitro mutants EC-4, EC-16 and EC-32, and a C31A
mutation in the in vivo evolved mutant Ec-2 (Figure 1). Of note,
it has been recently shown that mutations in this region cause an
increase in plasmid copy number (Kurpiel and Hanson, 2012).
No other point mutations potentially associated with FEP
resistance were identified in the in vitro resistant mutants.
However, the in vivo evolved mutant Ec-2 harbored two non-
synonymous SNPs in the rpoC gene resulting in a G125R
and a V289A substitution in the subunit beta’ of the DNA-
directed RNA polymerase.
Gene Transcription Levels and Plasmid
Copy Number
Since an increase in the expression levels of the blaCMY gene
or a decrease in the transcription of the porin-encoding genes
ompF and ompC may be involved with FEP resistance, the mRNA
levels of these genes were evaluated for all strains. The mutants
evolving from Ec-1 exhibited 2- to 14-fold increases in blaCMY
transcription compared to the parental strain Ec-1. For the
in vitro mutants, higher levels of blaCMY transcription correlated
TABLE 1 | MICs, sequence type, CMY variant and number of passages with cefepime of E. coli Ec-1, and its cefepime-resistant derivatives.
Ec-1 Ec-2 EC-4 EC-16 EC-32
Antibiotic MIC, mg/L (interpretation)a Cefepimec 0.125 (S) 48 (R) 4 (I) 32 (R) 256 (R)
Ampicillin ≥32 (R) ≥32 (R) ≥32 (R) ≥32 (R) ≥32 (R)
Piperacillin-tazobactam ≤4 (S) 8 (S) 8 (S) 64 (R) 64 (R)
Ticarcillin-clavulanate ≤8 (S) ≥256 (R) ≥256 (R) ≥256 (R) ≥256 (R)
Cephalothinb ≥32 (R) ≥32 (R) ≥32 (R) ≥32 (R) ≥32 (R)
Cefoxitinb 64 (R) ≥128 (R) ≥128 (R) ≥128 (R) ≥128 (R)
Cefotaxime 4 (R) 64 (R) 64 (R) ≥128 (R) ≥128 (R)
Cefotaxime-clavulanate 4 (NA) 32 (NA) 32 (NA) 64 (NA) 64 (NA)
Ceftriaxone 8 (R) 128 (R) 128 (R) ≥256 (R) ≥256 (R)
Ceftazidime 16 (R) ≥256 (R) ≥256 (R) ≥256 (R) ≥256 (R)
Ertapenem ≤0.25 (S) ≤0.25 (S) ≤0.25 (S) ≤0.25 (S) ≤0.25 (S)
Imipenem ≤0.5 (S) ≤0.5 (S) ≤0.5 (S) ≤0.5 (S) ≤0.5 (S)
Meropenem ≤1 (S) ≤1 (S) ≤1 (S) ≤1 (S) ≤1 (S)
Ciprofloxacin ≤0.25 (S) ≤0.25 (S) ≤0.25 (S) ≤0.25 (S) ≤0.25 (S)
Amikacin ≤4 (S) ≤4 (S) ≤4 (S) ≤4 (S) ≤4 (S)
Gentamicin ≤1 (S) ≤1 (S) ≤1 (S) ≤1 (S) ≤1 (S)
Colistin ≤0. 25 (S) ≤0. 25 (S) ≤0. 25 (S) ≤0. 25 (S) ≤0. 25 (S)
Polymyxin Bb ≤0. 25 (S) ≤0.25 (S) ≤0.25 (S) ≤0. 25 (S) ≤0.25 (S)
Tigecycline ≤0.25 (S) ≤0.25 (S) ≤0.25 (S) ≤0.25 (S) ≤0.25 (S)
Aztreonam 4 (I) ≥32 (R) ≥32 (R) ≥32 (R) ≥32 (R)
Co-trimoxazole ≤0.5 (S) ≤0.5 (S) ≤0.5 (S) ≤0.5 (S) ≤0.5 (S)
Sequence type (ST)d ST131 ST131 ST131 ST131 ST131
CMY variant 2 33 69 69 69
Passages with cefepime (at 14 of MIC) – – 24 27 30
aAccording to the EUCAST criteria (v6.0, 2016). MIC values (besides for cefepime) were obtained implementing the GNX2F, and ESB1F plates (Trek diagnostics).
bAccording to CLSI criteria (M100-S26, 2016). cMIC was obtained using Etest R©. dThe ST type was determined with the MLST 1.8 tool available on the Center for
Genomic Epidemiology online platform.
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FIGURE 1 | Sequence of the inc promoter and hairpin loop region in strain
Ec-1 and its in vitro and in vivo mutant derivatives [adapted from Kurpiel and
Hanson, 2012] Point mutations are denoted with bold nucleotides. Underlined
sequences represent complementary sequence arms of the inc RNA stem
loop. The transcriptional start site and putative −10 and −35 promoter
hexamers for inc are highlighted in gray.
with higher MICFEP, whereas the clinical mutant strain Ec-2
showed the lowest increase in transcription levels (approximately
twofold) (Table 2). Since the mutations identified in inc may
be associated with an increase in plasmid copy number, which
could explain the observed increase in blaCMY transcription, we
quantified and compared the copy number of the IncI1 plasmid
of Ec-1, and its resistant derivatives. All mutants showed increases
in plasmid copy number compared to Ec-1, i.e., 2- to 3-fold in
the in vitro mutants and 1.4-fold in the in vivo evolved mutant
CMY-33 (Table 2).
Transcript levels of ompC gradually decreased up to twofold
in the in vitro and in vivo mutants compared to Ec-1. A similar
pattern was observed in the transcript levels of ompF in the
in vitro mutants, but not in the in vivo mutant strain Ec-2
(Table 2). Consistently, SDS PAGE analysis did not evidence any
lack of OMPs in the resistant strains (Supplementary Figure S2).
Growth Kinetics
We next evaluated the in vitro fitness of the mutant strains
compared to Ec-1 in terms of growth under laboratory
conditions. Plotting OD450 against time revealed that all resistant
strains evolved from Ec-1 exhibited a slight growth defect
compared to the parental strain (Figure 2). However, there was
no statistically significant difference in the relative growth rates
of the mutant strains compared to Ec-1 (Figure 2).
DISCUSSION
Reports of FEP resistance evolution in CMY-2-producing E. coli
isolates are still rare. However, there has been a constant increase
in the number of such strains isolated from different sources, such
as humans, animals and food in Switzerland, as well as in other
parts of the world (Liebana et al., 2013; Seiffert et al., 2013a,b).
Furthermore, detection of AmpC production and differentiation
from ESBL-phenotypes is problematic in diagnostic laboratories,
or might not be sought after following a negative confirmatory
test for ESBLs, which could potentially lead to underestimate the
prevalence of AmpC-producers (Jacoby, 2009).
Switzerland is among the major consumers of FEP per capita
in Europe (Pluss-Suard et al., 2012), which could favor the
selection of resistant mutants. Low antibiotic levels at the site of
infection due to suboptimal dosing or inadequate distribution in
some body compartments and tissues represent a major driver
in resistance evolution (Andersson and Hughes, 2014). In this
regard, FEP concentrations in the lung tissues seem to reflect
blood concentrations well (Breilh et al., 2001), but were also
shown to be extremely variable in critically ill patients (Lipman
et al., 1999). Of note, some patients in the latter study showed
very low plasma levels of FEP, i.e., in a range that could potentially
promote resistance evolution in Pseudomonas aeruginosa (Fantin
et al., 1994). For this reason, alternative dosing regimens, such
as continuous infusion, were suggested as valuable options to
maintain sustained drug levels over time (Boselli et al., 2003).
In this study, we show that in vitro exposure of the blaCMY−2-
expressing Ec-1 strain to sublethal concentrations of FEP leads
to the selection of FEP-resistant mutants with similar resistance
mechanisms as observed in vivo, i.e., mutations in blaCMY and an
increase in its transcript levels.
The evolution of CMY-2 to CMY-69 under selective pressure
confirms the H-10 helix as a mutational hotspot in this class C
β-lactamase in the development of FEP resistance. In fact, it has
been previously shown that insertions, deletions, or substitutions
in the H-10 helix of class C β-lactamases may result in the
expansion of the substrate spectrum by an increased hydrolytic
activity due to a better accommodation of cephalosporins, such
as FEP, into the active site (Kim et al., 2006). It is interesting to
TABLE 2 | Relative fold changes of transcription levels and IncI1 plasmid copy number in Ec-1 and its cefepime-resistant derivativesa.
Strain Relative ompF transcript
level ± SD
Relative ompC transcript
level ± SD
Relative blaCMY
transcript level ± SD
Relative IncI1 plasmid
copy number ± SD
Ec-1 1 1 1 1
EC-4 1.74 ± 0.54 1.09 ± 0.19 4.27 ± 0.2 2.27 ± 0.42
EC-16 0.91 ± 0.52 0.85 ± 0.06 12.76 ± 0.95 2.36 ± 0.24
EC-32 0.60 ± 0.09 0.53 ± 0.03 14.12 ± 0.37 2.79 ± 0.07
Ec-2 1.06 ± 0.31 0.54 ± 0.1 2.48 ± 0.04 1.4 ± 0.02
SD, standard deviation. aAll transcript levels are relative to Ec-1.
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note that evolution of the CMY-2 occurred in vitro through a
SNP in the H-10 helix, while in vivo through a 6 bp deletion in
the same region. The latter genetic event is less likely to occur
and raises the question, whether a more radical modification
of the enzyme’s active site is needed for the development of
FEP resistance in vivo. Of note, Ec-2 exhibited a 10-fold higher
MICFEP compared to EC-4, despite the lower blaCMY mRNA
levels. Deletions in the H-10 helix of the CMY-33 or CMY-44
variants were previously associated with reduced susceptibility
to FEP in clinical E. coli isolates, with the MICFEP ranging
from 6 to 96 mg/L among the tested CMY-33-producing strains
(Doi et al., 2009). Nevertheless, the variability in the MICFEP
also suggested that additional background-specific genetic factors
may contribute to FEP resistance (Doi et al., 2009).
Overproduction of the beta-lactamase, as well as reduced
drug permeation due to the loss or downregulation of porins,
such as OmpF and OmpC, represent other common resistance
mechanisms known to affect beta-lactam resistance in E. coli,
and, notably, both mechanisms were recently linked to the
development of carbapenem resistance in blaCMY−2-harboring
E. coli, both in clinical isolates and in-vitro generated mutants
(Goessens et al., 2013; van Boxtel et al., 2017). In contrast
to this previous study, in which porin loss represented the
first step in the evolution of meropenem resistance, only a
slight downregulation of porins (mainly of OmpC), which
was not detectable on SDS page analysis, was observed in
the in vivo and in vitro mutants. This is consistent with
previous observations suggesting that porin deficiency may
have little impact in the development of FEP resistance in
E. coli (Chen and Livermore, 1993). However, all mutants
deriving from Ec-1 showed an increase in blaCMY transcript
levels. Particularly the in vitro mutants showed a gradual
increase in blaCMY mRNA compared to Ec-1 over time under
constant selective pressure, which correlated with higher FEP
MICs. Additionally, EC-16 and EC-32 developed resistance
against piperacillin/tazobactam, while the parental strain and the
other derivative mutants were susceptible. This phenomenon
is likely attributable to the higher blaCMY transcript levels
in these two strains, consistent with a recent finding of a
correlation between higher transcription levels of this gene
and higher piperacillin/tazobactam MICs (Kurpiel and Hanson,
2012). However, while in this previous study the increase
in blaCMY mRNA perfectly correlated with the increase in
plasmid copy number, in our study the 2- to 3-fold increase
in plasmid copy number due to mutations in the inc antisense
RNA gene could only partially account for the up to 14-fold
increase in transcript levels. Based on our WGS data, we were
unable to pinpoint any additional mutations, including in the
promoter region of blaCMY, or any duplication or transposition
events, which could explain this phenomenon. Thus, some
transcriptional or posttranscriptional regulatory mechanisms
may be involved in the observed increase of the blaCMY mRNA
levels over time, although we cannot completely exclude an
unidentified genetic factor.
Interestingly, we identified in the in vivo mutant Ec-2 two
mutations in rpoC which may represent compensatory mutations
that could broadly affect gene transcription, and explain the
FIGURE 2 | Growth kinetics of strain Ec-1 and its in vitro and in vivo mutant
derivatives. The mean OD450 (±SEM) over time of three biological replicates is
shown for Ec-1 (filled circles), EC-4 (filled squares), EC-16 (filled triangles),
EC-32 (open squares), and Ec-2 (open circles). The inset shows the relative
growth rate in minutes for each mutant strain compared to the parental strain.
lower blaCMY−2 transcript levels compared to the in vitro
deriving strains. However, these mutations may also be directly
associated with FEP resistance. For instance, a mutation in
rpoC was previously shown to be sufficient, in absence of
any additional resistance determinants, to induce cephalosporin
resistance in Bacillus subtilis (Lee et al., 2013) due to an increase
of the expression of alternative σ factors, which control the
transcription of genes in response to cell envelope stress.
Eﬄux did not seem to play a major role in the FEP resistance of
the Ec-1 derivatives, since MICs in the presence of PAbN, a broad-
spectrum inhibitor of RND pumps in Gram-negative bacteria
(Fernandez and Hancock, 2012), remained unaltered.
All mutants only exhibited a slight growth defect and no
difference in terms of relative growth rate compared to the
parental strain, indicating that, at least during growth in rich
medium under laboratory conditions, there was no considerable
fitness cost associated with the resistant phenotype. These in vitro
conditions do not mimic the environment encountered by the
bacteria in the host, however, the fact that Ec-2 evolved from Ec-1
in vivo, highlights the possibility that such strains may be able to
successfully adapt and survive in a particular niche, such as in the
lung or in abscesses, under selective pressure.
In conclusion, our study shows that mutations in blaCMY
and increase of its transcript levels are common resistance
mechanisms involved in the development of FEP resistance under
selective pressure both in vitro and in vivo. We acknowledge
that further studies are needed to fully characterize the
observed mechanisms of resistance and their contribution in
the development of FEP resistance. However, our observations
advocate for the importance to detect and differentiate AmpC
and ESBL production in diagnostic laboratories and indicate
that clinicians should be aware of the potential development
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of FEP resistance in CMY-2-producing E. coli isolates, most
probably as a consequence of suboptimal drug concentrations
during FEP treatment. We showed that exposure to sub-lethal
concentrations of FEP resulted in a continuous increase in
the MICFEP, suggesting that resistance to this drug in CMY-2-
producing strains may increase over time just as a consequence
of suboptimal drug concentrations. Therefore, optimized dosing
strategies, e.g., by shorter dosing intervals or continuous infusion
of FEP led by therapeutic drug monitoring, may be considered as
valuable options for maintaining adequate drug levels and avoid
resistance evolution.
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